Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-15
2007-05-15
Wehbe′, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C424S278100, C435S320100, C530S350000
Reexamination Certificate
active
09768917
ABSTRACT:
Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dentritic cells to the site of antigen delivery. An increase number of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.
REFERENCES:
patent: 2002/0071825 (2002-06-01), Schall et al.
patent: 0 974 357 (2000-01-01), None
patent: 0 974 357 (2000-01-01), None
patent: WO94/07521 (1994-04-01), None
patent: WO94/13321 (1994-06-01), None
patent: WO94/21277 (1994-06-01), None
patent: WO95/17092 (1995-06-01), None
patent: WO96/34891 (1996-11-01), None
patent: WO97/19696 (1997-06-01), None
patent: WO97/31098 (1997-08-01), None
patent: WO97/41831 (1997-11-01), None
patent: WO98/01557 (1998-01-01), None
patent: WO 98/14573 (1998-04-01), None
patent: WO98/14573 (1998-04-01), None
patent: WO 99/46392 (1999-09-01), None
patent: WO 00/09151 (2000-02-01), None
Fayette et al. (1998) Scand. J. Immunol., vol. 48, 563-570.
Youseff, S. et al., 2000, “CC-Chemokine-Encoding DNA Vaccines Enhance Break down of Tolerance to their Gene Products and Treat Ongoing Adjuvant Arthritis”J. Clin. Invest.106:361-371.
Xin, K.Q. et al., 1999, “Immunization of RANTES Expression Plasmid with a DNA Vaccine Enhances HIV-1 Specific Immunity”Clin. Immunol.92:90-96.
Sin, J. et al., 2000, “DNA Vaccines Encoding Interleukin-8 and RANTES Enhance Antigen-Specific Th1-type (CD4(+) T-cell-medicated Protective Immunity against Herpes Simplex Virus Type 2 in Vivo.”J. Virol.74:11173-11180.
Nomura, T. et al.; 2000, “Chemokines and Anti-cancer Immunotherapy”Anticancer Res.20:4073-4080.
Lu, Y. et al., 1999, “Macrophage Inflammatory Protein 1 Alpha Expression Plasmid enhances DNA Vaccine-Induced Immune Response Against HIV-1”Clin Exp. Immunol.115:335-341.
Lehner, T. et al., 2000, “Heat Shock Proteins Generate Beta-Chemokines which Function as innate adjuvants enhancing Adaptive Immunity”Eur. J. Immunol.30:594-603.
Laning, J. et al., 1994, “Inhibition of in Vivo Tumor Growth by the Beta Chemokine, TCA3”J. Immunol.153:4625-4635.
Kim, J.J. et al., 2000, “Chemokine Gene Adjuvants can Modulate Immune Responses Induced by DNA Vaccines”J. Interferon Cytokine Res.20:487-498.
Braun, S.E. et al., 2000, “The CC Chemokine CK Beta-11/MIP-3 beta/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells through NK Cells”J. Immunol.164:4025-4031.
Biragyn, A. et al., “Genetic Fusion of Chemokines to Self Tumor Antigen Induces Protective, T-Cell dependent Antitumor Imunnity”Nat. Biotechnol.17:253-258.
Caux et al., “Dendritic cell biology and regulation of dendritic cell trafficking by chemokines”,Springer Seminar in Immunopathology, vol. 22, No. 4, pp. 345-369 (2000).
Dieu-Nosjean et al., “Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines”,J. Leukocyte Biology, vol. 66, No. 2, pp. 252-262 (1999).
Kellermann et al., “The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3β Are Potent Chemoattractants for In Vitro- and In Vivo- Derived Dendritic Cells”,J. Immunology, vol. 162, No. 7, pp. 3859-3864 (1999).
Nakamura et al., “Keratinocyte-Derived Monocyte Chemoattractant Protein 1 (MCP-1): Analysis in a Transgenic Model Demonstrates MCP-1 Can Recruit Dendritic and Langerhans Cells to Skin”,J. Investigative Dermatology, vol. 105, No. 5, pp. 635-643 (1995).
Vecchi et al., “Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells”,J. Leukocyte Biology, vol. 66, No. 3, pp. 489-494 (1999).
Xu et al., “Human recombinant monocyte chemotactic protein and other c-c chemokines bind and induce directional migration of dendritic cells in vitro”,J. Leukocyte Biology, vol. 60, No. 3, pp. 365-371 (1996).
Zhu et al., “Human monocyte-derived dendritic cells expresing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines”,Chinese Medical Journal(English Edition), vol. 113, No. 12, pp. 1124-1128 (2000).
Fioretti et al., “Reduced Tumorigenicity and Augmented Leukocyte Infiltration After Monocyte Chemotactic Protein-3 Gene Transfer”J. Immunol.161(1):342-346, (1998).
Dematos et al., 1998, “Pulsing of Dentritic Cells with Cell Lysates from either B16 melanoma or MCA-106 Fibrosarcome Yields Equally Effective Vaccines Against B16 Tumors in Mice”J Surg. Oncol.68(2):79-91.
Vicari et al., 2000, “Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms”J Immunol.165:1992-2000.
Caux Christophe
Vicari Alain P.
Reed Grant E.
Schering Corporation
Wehbe′ Anne M.
LandOfFree
Chemokines as adjuvants of immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokines as adjuvants of immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokines as adjuvants of immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802396